Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec:358:104235.
doi: 10.1016/j.cellimm.2020.104235. Epub 2020 Oct 11.

Immunogenic properties of immunoglobulin superfamily members within complex biological networks

Affiliations
Review

Immunogenic properties of immunoglobulin superfamily members within complex biological networks

Josué Odales et al. Cell Immunol. 2020 Dec.

Abstract

Antibodies, T cell receptors and major histocompatibility complex molecules are members of the immunoglobulin superfamily and have pivotal roles in the immune system. The fine interrelation between them regulates several immune functions. Here, we describe lesser-known functions ascribed to these molecules in generating and maintaining immune response. Particularly, we outline the contribution of antibody- and T cell receptor-derived complementarity-determining region neoantigens, antigenized antibodies, as well as major histocompatibility complex class I molecules-derived epitopes to the induction of protective/therapeutic immune responses against pathogens and cancer. We discuss findings of our own and other studies describing protective mechanisms, based on immunogenic properties of immunoglobulin superfamily members, and evaluate the perspectives of application of this class of immunogens in molecular vaccines design.

Keywords: Anti-idiotype; Complementarity-determining region; Immune network; Immunoglobulin; MHC; TCR.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Basic interactions between Ig superfamily members within immunological network. (A) According to Jerne’s network theory, an antibody (Ab2) can bind to the variable region of antigen (Ag)-specific Ab (Ab1) and trigger a successive cascade of anti-anti-antibody production (Ab3). The anti-idiotypic Ab2 carries the internal image/mimotopes of the original Ag in CDRs and is capable to generate anti-anti-idiotypic B and T cell responses reinforcing the immune response to the original Ag. This class of immunogens (Ab2) was used as a vaccine against cancer and several pathogens. Similarly, the TCR beta chain (idiotypic TCR) generates TCR-specific Ab and anti-idiotypic Ag-specific T cell responses. (B) In transplant rejection, within graft-versus-host (GVH) interactions, apparently both auto- and allo-immunity are involved. The B cells produce MHC and non-MHC Abs, as well as Abs against mismatched minor Histocompatibility Antigens (mHC). The T cells can damage the graft by directly recognizing donor’s MHC or by eliminating target cells through p-MHC/TCR interaction, where peptides are derived from MHC molecules (undirect recognition). By a similar manner, the T cells may eliminate tumor cells through recognition of self MHC-derived peptides. (C) The antigenized Abs are immunoglobulins where T cell epitopes are inserted within CDRs, which convert them in effective vaccine immunogens targeting pathogens and tumor cells.

Similar articles

Cited by

References

    1. Natarajan K., Mage M.G., Margulies D.H. eLS. John Wiley & Sons Ltd; Chichester: 2015. Immunoglobulin Superfamily; pp. 1–7. - DOI
    1. Slansky J.E., Jordan K.R. The Goldilocks model for TCR-too much attraction might not be best for vaccine design. PLoS Biol. 2010;8:1–5. doi: 10.1371/journal.pbio.1000482. - DOI - PMC - PubMed
    1. Chames P., Van Regenmortel M., Weiss E., Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 2009;157:220–233. doi: 10.1111/j.1476-5381.2009.00190.x. - DOI - PMC - PubMed
    1. D.M. Ecker, S.D. Jones, H.L. Levine, The therapeutic monoclonal antibody market, mAbs 7 (2015) 9–14. https://doi.org/ 10.4161/19420862.2015.989042. - PMC - PubMed
    1. Landolina N., Levi-Schaffer F. Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17. Br. J. Pharmacol. 2016;173:793–803. doi: 10.1111/bph.13396. - DOI - PMC - PubMed

MeSH terms